XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER LEFT
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
-1.00 · LEFT
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
-0.500 · CENTER LEFT
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg 0.005
1,002 articles tracked
7-day bias trend
LcenterR
Article Excerpt
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX […]
Read full article at Financial Post ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
pending
Jun 12, 2026